2. Induced Disease Models Products NF-κB
  3. Urinary System Disease Models NF-κB
  4. Aristolochic acid A

Aristolochic acid A  (Synonyms: Aristolochic acid I; TR 1736)

Cat. No.: HY-N0510 Purity: 99.91%
SDS COA Handling Instructions

Molarity Calculator

Aristolochic acid A (Aristolochic acid I; TR 1736) is the main component of plant extract Aristolochic acids, which are found in various herbal plants of genus Aristolochia and Asarum. Aristolochic acid A significantly reduces both activator protein 1 (AP-1) and NF-κB activities. Aristolochic acid A reduces BLCAP gene expression in human cell lines.

For research use only. We do not sell to patients.

Aristolochic acid A Chemical Structure

Aristolochic acid A Chemical Structure

CAS No. : 313-67-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
5 mg USD 32 In-stock
10 mg USD 50 In-stock
25 mg USD 70 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Aristolochic acid A:

Aristolochic acid A Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Aristolochic acid A (Aristolochic acid I; TR 1736) is the main component of plant extract Aristolochic acids, which are found in various herbal plants of genus Aristolochia and Asarum. Aristolochic acid A significantly reduces both activator protein 1 (AP-1) and NF-κB activities. Aristolochic acid A reduces BLCAP gene expression in human cell lines[1].

Cellular Effect
Cell Line Type Value Description References
HEK293 EC50
118.34 μM
Compound: Aristolochic acid
Cytotoxicity in HEK293 cells assessed as reduction in cell survival incubated for 48 hrs by MTT assay
Cytotoxicity in HEK293 cells assessed as reduction in cell survival incubated for 48 hrs by MTT assay
[PMID: 30108751]
Neutrophil IC50
> 10 μg/mL
Compound: 4
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins
[PMID: 21353775]
Neutrophil IC50
> 10 μg/mL
Compound: 4
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins
[PMID: 21353775]
In Vitro

Aristolochic acid A (150, 200 μM, 24 hours) inhibits the cell viabilities of kidney cells HEK293 and HK-2[1].
Aristolochic acid A (100, 200 μM, 24 hours) causes a concentration-dependent decrease in bladder cancer-associated protein (BLCAP) mRNA levels in kidney cells (HEK 293 and HK-2) , and bladder cancer cell line (HT-1376)[1].
Aristolochic acid A (100, 200 μM, 24 hours) weakens the BLCAP protein signals in a dose-dependent manner in both HEK293 and HT-1376 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Aristolochic acid A Related Antibodies

Cell Viability Assay[1]

Cell Line: Kidney cells (HEK 293 and HK-2)
Concentration: 50, 100, 150, 200 μM
Incubation Time: 24 hours
Result: The cell viabilities of HEK293 and HK-2 were lower than that of vehicle-treated cultures until 150 μM and 200 μM.

RT-PCR[1]

Cell Line: Kidney cells (HEK 293 and HK-2), and bladder cancer cell line (HT-1376)
Concentration: 100, 200 μM
Incubation Time: 24 hours
Result: Down regulated the levels of BLCAP mRNA.

Western Blot Analysis[1]

Cell Line: HEK293 and HT-1376 cells
Concentration: 100, 200 μM
Incubation Time: 24 hours
Result: Reduced the BLCAP protein expression in a dose-dependent manner.
In Vivo

Aristolochic acid A can be used to induce nephrotoxicity models. Pharmacokinetic studies show that in male C57BL/6 mice, the concentration of Aristolochic acid A in the kidneys is higher than in the liver 30 minutes after intraperitoneal administration (10 mg/kg). The plasma concentration of Aristolochic acid A also peaks approximately 30 minutes after administration.

Induction of Nephrotoxicity [2][3]
Background
The pathogenesis of Aristolochic acid Anephropathy remains unclear. Research shows that Aristolochic acid A mainly damages renal tubular epithelial cells and renal tules, leading to interstitial fibrosis, thereby producing nephrotoxicity.
Specific Mmodeling Methods
Mice: C57BL/6J • 8 weeks of age
Administration: 10 mg/kg • i.p. • 3-5 days[3]
Note
Modeling Indicators
Pathology changs: H&E stain shows renal tissue structure is disordered, glomerular edema, pyknosis, and proximal tubule epithelial cell shedding
Biochemistry changes: Scr and blood urea nitrogen (BUN) contents increases
Correlated Product(s): /
Opposite Product(s): /

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

341.27

Formula

C17H11NO7
CAS No.
Appearance

Solid

Color

Light yellow to orange

SMILES

OC(C1=CC2=C(OCO2)C3=C4C(C(OC)=CC=C4)=CC([N+]([O-])=O)=C31)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 16.67 mg/mL (48.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9302 mL 14.6512 mL 29.3023 mL
5 mM 0.5860 mL 2.9302 mL 5.8605 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (6.09 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.91%

SDS (583 KB)

COA (258 KB) LCMS (101 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.9302 mL 14.6512 mL 29.3023 mL 73.2558 mL
5 mM 0.5860 mL 2.9302 mL 5.8605 mL 14.6512 mL
10 mM 0.2930 mL 1.4651 mL 2.9302 mL 7.3256 mL
15 mM 0.1953 mL 0.9767 mL 1.9535 mL 4.8837 mL
20 mM 0.1465 mL 0.7326 mL 1.4651 mL 3.6628 mL
25 mM 0.1172 mL 0.5860 mL 1.1721 mL 2.9302 mL
30 mM 0.0977 mL 0.4884 mL 0.9767 mL 2.4419 mL
40 mM 0.0733 mL 0.3663 mL 0.7326 mL 1.8314 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Aristolochic acid A Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Aristolochic acid A313-67-7Aristolochic acid I TR 1736TR1736TR 1736TR-1736NF-κBNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Aristolochic acid A
Cat. No.:
HY-N0510
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (583 KB) Français - FR (583 KB) Deutsch - DE (583 KB) Norwegian - NO (583 KB) Español - ES (583 KB) Swedish - SV (583 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.